These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8054461)

  • 1. Fragmin (LMWH) vs heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting.
    Bagge L; Holmer E; Wahlberg T; Nyström SO; Tydén H
    Blood Coagul Fibrinolysis; 1994 Apr; 5(2):273-80. PubMed ID: 8054461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model.
    Bagge L; Wahlberg T; Holmer E; Tydén H; Nyström SO; Malm T
    Blood Coagul Fibrinolysis; 1994 Apr; 5(2):265-72. PubMed ID: 8054460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
    Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
    Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
    Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
    Bagge L; Borowiec JW; Thelin S; Hultman J
    Scand Cardiovasc J; 1997; 31(5):275-81. PubMed ID: 9406294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
    Bagge L; Borowiec JW; Thelin S; Hultman J
    Scand Cardiovasc J; 1997; 31(6):275-81. PubMed ID: 9498931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of extrinsic hemostasis activation by low-molecular-weight heparin.
    Stief TW
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):633-7. PubMed ID: 17102649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.
    Alhenc-Gelas M; Jestin-Le Guernic C; Vitoux JF; Kher A; Aiach M; Fiessinger JN
    Thromb Haemost; 1994 Jun; 71(6):698-702. PubMed ID: 7974334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose.
    Teligui L; Dalmayrac E; Mabilleau G; Macchi L; Godon A; Corbeau JJ; Denommé AS; Bouquet E; Boer C; Baufreton C
    Interact Cardiovasc Thorac Surg; 2014 Jun; 18(6):763-9. PubMed ID: 24632424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
    ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass.
    Chan AK; Leaker M; Burrows FA; Williams WG; Gruenwald CE; Whyte L; Adams M; Brooker LA; Adams H; Mitchell L; Andrew M
    Thromb Haemost; 1997 Feb; 77(2):270-7. PubMed ID: 9157580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery.
    Patteril M; Stafford-Smith M; Toffaletti JG; Bute BP; Milano CA; Welsby IJ
    Clin Chim Acta; 2005 Jun; 356(1-2):218-24. PubMed ID: 15936321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.